Navigation Links
EntreMed's ENMD-2076 Active in Solid and Hematological Cancers
Date:11/16/2009

ROCKVILLE, Md., Nov. 16 /PRNewswire-FirstCall/ -- EntreMed, Inc. ( ENMD), a clinical-stage pharmaceutical company developing therapeutics for the treatment of cancer today announced the presentation of data for the Phase 1 study for its Aurora A/angiogenic kinase inhibitor, ENMD-2076, in leukemia patients. The Company also announced that it has selected ovarian cancer as an initial Phase 2 indication.

Phase 1 Leukemia Data

Initial data for the Phase 1 clinical study with ENMD-2076 in patients with relapsed or refractory acute myeloid leukemia (AML) were presented by principal investigator, Dr. Karen Yee, at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics being held this week in Boston, Massachusetts. Early results for the study in hematological cancers demonstrated that ENMD-2076, administered orally as a single agent, was well tolerated. Data for 15 evaluable patients showed that one patient achieved a CRi (complete remission with incomplete hematological recovery) and two patients achieved a morphologic leukemia-free state (MLFS). Three additional patients experienced 11%, 14%, and 65% reductions in marrow blast count. The AML study continues to enroll patients and pharmacodynamic and pharmacokinetic activity is being monitored.

Ovarian Cancer - Initial Phase 2 Indication

While early Phase 1 data from the leukemia study are encouraging, the Company has selected ovarian cancer as its initial Phase 2 indication. This decision is supported by data from the ongoing Phase 1 study with ENMD-2076 in patients with solid tumors where of the 20 ovarian cancer patients, tumor and tumor marker responses were demonstrated in 45% of patients. In addition, another 15% have shown clinical benefit including reductions in tumor size, improvement in symptoms, or both. The decision is further supported by robust preclinical data and the need for additional active age
'/>"/>

SOURCE EntreMed, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Entremed Presents Results of ENMD-2076 Phase 1 Study in Advanced Cancer Patients
2. EntreMed Presents Initial Clinical Results for ENMD-2076
3. EntreMed to Highlight ENMD-2076 Kinase Inhibitor at 2008 AACR Annual Meeting
4. EntreMed Achieves a Key Milestone Through Initiation of ENMD-2076 Clinical Program
5. Glamour Magazine Woman of the Year and MISSION Skincare Co-Founder, Serena Williams, Teams Up with CVS/pharmacy to Launch National Active Lifestyle Skincare Destinations
6. Trana Discovery and Southern Research Institute Find Bioactive HIV Antiviral Compounds
7. Accurays Treatment Planning Service Active at 20 Percent of U.S. CyberKnife Centers
8. MolSofts New Technology Brings Online Publications to Life in Fully Interactive 3D
9. Medcos 2010 Medicare Prescription Drug Plan Helps People Take an Active Part in Lowering Prescription Costs
10. Tata Interactive Systems Partners With Bersin & Associates for Exclusive Executive Learning Forum - TLF 2009
11. Alba Therapeutics Announces Enrollment of Its First European Patient in Global Phase IIb Study of Larazotide Acetate for Treatment of Active Celiac Disease
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/19/2014)... Dec. 19, 2014 Breckenridge Pharmaceutical, Inc. announced ... with MSN Laboratories Pvt. Ltd. ( Hyderabad, India ... commercialize several new ANDAs.  Under the terms of the ... exclusively to Breckenridge for the U.S. market, and Breckenridge ... Breckenridge and MSN have agreed to develop an oral ...
(Date:12/19/2014)... N.C. , Dec. 19, 2014 ... optimize a product,s web presence to reflect the ... websites, in particular, must meet the needs of ... and culture. According to recent ... than half of the participating companies averaged more ...
(Date:12/19/2014)... , Dec. 19, 2014  Monarch America Inc. (OTCQB: ... Corp.) is pleased to provide this review of the ... in 2015. "Over this past year, we ... I am extremely proud to say that Monarch America ... than it has ever been," stated Eric Hagen ...
Breaking Medicine Technology:Breckenridge Pharmaceutical signs Multi-Product Generic Agreement with MSN Laboratories Pvt. Ltd. 2Building a Best-in-Class Pharma Global Brand Website 2Monarch America Inc. CEO Reviews Recent Achievements and Provides Outlook for 2015 2Monarch America Inc. CEO Reviews Recent Achievements and Provides Outlook for 2015 3
(Date:12/19/2014)... Energy Textiles is excited to announce ... the world’s leading responsive textile, can now be ... are a number of benefits to wearing Celliant, ... balanced body temperature; which can lead to enhanced ... athletic performance; and overall wellness. In addition, the ...
(Date:12/19/2014)... These vanadium reserves are mostly found ... 151,000 tons of vanadium were produced globally in 2013, ... increased at 6.7% AAGR during the period from 2001 ... being the largest consumer, accounted for more than 90% ... alloy and the chemical industry. , View Full Report ...
(Date:12/19/2014)... (HealthDay News) -- The intestinal bacteria that cause inflammatory ... may be inherited, researchers report. The findings, published ... help in efforts to prevent the disease and treat ... study authors added. "The intestinal bacteria, or ,gut ... have a big impact on your health for the ...
(Date:12/19/2014)... News) -- The cost of cancer treatment can cause ... finds. Researchers examined data from 1,000 people in ... or lung cancer. Of those patients, almost 900 had ... 100 had advanced cancer. Nearly half of the ... bills, which was linked with a poorer health-related quality ...
(Date:12/19/2014)... B. E. Smith, the only full-service leadership ... retained to lead a national chief financial officer ... Park, Colo. The top executive search firm in the ... than 900 healthcare executives into organizations. , Estes ... access hospital and level IV trauma center, with a ...
Breaking Medicine News(10 mins):Health News:Energy Textiles Launches Celliant Revitalizing Bedsheets 2Health News:Marketresearchreports.biz: Global Vanadium Usage Increased at AAGR of 6.7% between 2001 and 2013 2Health News:Marketresearchreports.biz: Global Vanadium Usage Increased at AAGR of 6.7% between 2001 and 2013 3Health News:Crohn's, Colitis May Have Genetic Underpinnings, Study Finds 2Health News:Cancer Treatment Costs Weigh Heavily on Patients, Study Finds 2Health News:Estes Park Medical Center Retains B. E. Smith to Recruit New Chief Financial Officer 2Health News:Estes Park Medical Center Retains B. E. Smith to Recruit New Chief Financial Officer 3
... meet increasing demand for,pharmaceutical packaging in China, ... HON ) announced,today that it has signed a ... Ltd., to provide the Chinese company with,Honeywell,s Aclar(R) ... also provide technical services and training to Haishun,as ...
... 6 CJPS Enterprises, LLC (, http://www.CJPS-Enterprises.com ... resources,to help companies that depend on the automotive ... "Although both industries seem similar in what they ... companies trying to embark,on this diversification initiative have ...
... an independent factor in cancer survival rates and should not ... a study in the November issue of IJCP , ... team of hospital and University-based researchers from Barcelona, Spain, carried ... with cancer. , "We found that there were a ...
... in German . , Opting for ... warning signs of lymphedema: that,s how women with breast ... German Institute for Quality and Efficiency in Health Care ... themselves from this common and distressing adverse effect of ...
... Conference on Cell Therapy for Cardiovascular Disease (IC3D) ... evolving field of cell-based therapies for treating cardiovascular ... "Cellular and Molecular Building Blocks: Strategies for Cardiovascular ... will convene to present basic, core discussions on ...
... 6 Let,s face it: Because of the,economy, typical ... are,becoming luxuries. Today,s budget trimmers who regularly attend a ... make a small,investment in a home yoga practice and ... Balanced Living magazine,s November,issue, now on newsstands, features "The ...
Cached Medicine News:Health News:Honeywell Signs Supply Agreement with Chinese Company for Aclar(R) Film 2Health News:Honeywell Signs Supply Agreement with Chinese Company for Aclar(R) Film 3Health News:CJPS Enterprises to Increase Focus on Automotive Diversification 2Health News:Age is not a key factor in cancer survival, but clinical trials exclude older patients 2Health News:Age is not a key factor in cancer survival, but clinical trials exclude older patients 3Health News:How women can improve their quality of life after breast cancer treatment 2Health News:5th Annual Global Conference on Stem Cell Therapy to be held Jan. 13-16, 2009 in NYC 2Health News:In These Stressful, Budget-Busting Times, It's Wise to Invest in a Home Yoga Practice, Says Natural Solutions Magazine 2
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
Medicine Products: